Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Sonnet BioTherapeutics Analyst Ratings and Price Targets | NASDAQ:SONN | Benzinga
Sonnet BioTherapeutics Holdings Inc has a consensus price target of $10.18 based on the ratings of 4 analysts. The high is $20 issued by Chardan Capital on March 28, 2025. The low is $6.7 issued by EF Hutton on August 23, 2023. The 3 most-recent analyst ratings were released by Chardan Capital on March 28, 2025, December 20, 2024, and August 23, 2024, respectively. With an average price target of $23.33 between Chardan Capital, there's an implied 1838.95% upside for Sonnet BioTherapeutics Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
EF Hutton
Ladenburg Thalmann
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Sonnet BioTherapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | 1561.96% | Chardan Capital | Keay Nakae22% | $20 → $20 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 1561.96% | Chardan Capital | Keay Nakae22% | $30 → $20 | Maintains | Buy | Get Alert |
| 08/23/2024 | Buy Now | 2392.94% | Chardan Capital | Keay Nakae22% | $240 → $240 | Maintains | Buy | Get Alert |
| 05/28/2024 | Buy Now | 2392.94% | Chardan Capital | Keay Nakae22% | $240 → $240 | Maintains | Buy | Get Alert |
| 05/16/2024 | Buy Now | 481.69% | EF Hutton | Tim Moore57% | $88 → $56 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 2392.94% | Chardan Capital | Keay Nakae22% | $600 → $240 | Maintains | Buy | Get Alert |
| 11/27/2023 | Buy Now | 481.69% | Ladenburg Thalmann | Ahu Demir2% | → $56 | Initiates | → Buy | Get Alert |
| 08/23/2023 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Assumes | → Buy | Get Alert |
| 08/16/2023 | Buy Now | 897.17% | Chardan Capital | Keay Nakae22% | $2464 → $2112 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Assumes | → Buy | Get Alert |
| 05/11/2023 | Buy Now | 1063.37% | Chardan Capital | Keay Nakae22% | $2992 → $2464 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 1312.66% | Chardan Capital | Keay Nakae22% | $3872 → $2992 | Maintains | Buy | Get Alert |
| 02/15/2023 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | Buy Now | 456.76% | EF Hutton | Michael King44% | → $1179.2 | Initiates | → Buy | Get Alert |
| 09/22/2022 | Buy Now | 1728.15% | Chardan Capital | Keay Nakae22% | $352 → $3872 | Maintains | Buy | Get Alert |
| 08/16/2022 | Buy Now | 66.2% | Chardan Capital | Keay Nakae22% | $6160 → $4928 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Sonnet BioTherapeutics (SONN) stock?
The latest price target for Sonnet BioTherapeutics (NASDAQ:SONN) was reported by Chardan Capital on March 28, 2025. The analyst firm set a price target for $20.00 expecting SONN to rise to within 12 months (a possible 1561.96% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ:SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.
When was the last upgrade for Sonnet BioTherapeutics (SONN)?
There is no last upgrade for Sonnet BioTherapeutics
When was the last downgrade for Sonnet BioTherapeutics (SONN)?
There is no last downgrade for Sonnet BioTherapeutics.
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $20.00 to $20.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $1.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.